Scheme 1.

Construction a biomimetic nano-drug treat homocysteine (Hcy)-induced atherosclerosis by inhibiting macrophage pyroptosis. Additionally, this nano-drug improves the dysbiosis of gut microbes while reducing the inflammatory response and blood Hcy levels. PB: Prussian blue; NPs: nanoparticles; RVS: rosuvastatin; PR: RVS-loaded PB; MPR: macrophage membrane-coated PR; ZO-1: zonula occludens-1; ROS: reactive oxygen species; HIF-1α: hypoxia-inducible factor-1α; TLR4: Toll-like receptor 4; NF-κB: nuclear factor kappaB; NLRP3: oligomerization domain (NOD)-like receptor thermal protein domain associated protein 3; IL: interleukin; GSDMD: gasdermin D; N-GSDMD: N-terminal GSDMD.